Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-06-28
2011-06-28
Goddard, Laura B (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C424S133100
Reexamination Certificate
active
07968686
ABSTRACT:
The present invention relates to glucagon receptor polypeptide antagonists which inhibit the binding of the hormone glucagon to its receptor. More particularly, the present invention relates to high affinity glucagon receptor antibodies or Fab fragments thereof that inhibit binding of glucagon to its receptor and their use in the treatment or prevention of type 2 diabetes (NIDDM) and related disorders in mammalian species.
REFERENCES:
patent: 5770445 (1998-06-01), Kindsvogel et al.
patent: 5776725 (1998-07-01), Kindsvogel et al.
patent: 5919635 (1999-07-01), Kindsvogel et al.
patent: 0658200 (2004-12-01), None
patent: WO 02/45494 (2002-06-01), None
patent: WO 03/040309 (2003-05-01), None
patent: WO 2004/096016 (2004-11-01), None
patent: WO 2006/005469 (2006-01-01), None
patent: WO 2008/003641 (2008-01-01), None
patent: WO 2008/036341 (2008-03-01), None
Yan, et al.,J.Pharmacology and Experiemental Therapeutics, Fully Human Monoclonal Antibodies Antagonizing the Glucagon Receptor Improve Glucose Homeostasis in Mice and Monkeys,vol. 329, No. 1, pp. 102-111 (2009).
Sorensen, et al.,Diabetes, Immunoneutralization of Endogenous Glucagon Reduces Hepatic Glucose Output and hmproves Long-Term Glycemic Control in Diabeticob/obMice, vol. 55, No. 10, pp. 2843-2848 (2006).
Buggy et al.,Horm. Metab. Res. 28 (1996) 215-219.
Burcelin, et al.,Gene164 (1995) 305-310.
Co, et al.,Proc. Natl. Acad. Sci. USA88, 2869 (1991).
D'Orazio et al.,Clin. Chem. Lab. Med. 44(12): 1486-1490 (2006).
Etgen et al.,Metabolism49(5): 684-688 (2000).
Isaacs et al.,Clin. Exp. Immunol. 106:427-433 (1996).
Jones et al.,Nature, 321:522 (1986).
Kabat, et al.,Ann. NY Acad. Sci. 190:382-93 (1971).
Konno, et al.,Horm Metab Res. 37(2):79-83 (Feb. 2005).
McNally et al.,Peptides25 (2004) 1171-1178.
Riechmann et al.,Nature, 332:323-327 (1988).
Unson et al.,PNAS, 93:310-315, Jan. 1996.
Verhoeyen et al.,Science, 239:1534 (1988).
Wright et al.,Acta Cryst. (2000) D56:573-580.
Wu et al.,J. Mol. Biol., 294:151-162 (1999).
Cohen,Bioorg. Med. Chem., “Direct observation (NMR) of the efficacy of glucagon receptor antagonists in murine liver expressing the human glucagon receptor,” 14:1506-1517(2006).
Dallas-Yang, et al., “Hepatic glucagon receptor binding and glucose-lowering in vivo by peptidyl and non-peptidyl glucagon receptor antagonists,”Eur. J. Pharm., 501: 225-234 (2004).
Gelling, et al., “Lower blood glucose, hyperglucagonemia, and pancreatic α cell hyperplasia in glucagon receptor knockout mice,”Proc. Natl. Acad. Sci. USA, 100:1438-1443 (2003).
Iwanij, et al., “Characterization of the Glucagon Receptor and Its Functional Domains Using Monoclonal Antibodies,”J. Biol. Chem., 265(34):21302-21308 (1990).
Liang, et al., “Reduction in Glucagon Receptor Expression by an Antisense Oligonucleotide Ameliorates Diabetic Syndrome indb/dbMice,”Diabetes, 53:410-417 (2004).
Parker, et al., “Glycemic Control in Mice with Targeted Disruption of the Glucagon Receptor Gene,”Biochem. Biophys. Res. Commun., 290:839-843 (2002).
Sloop, et al., “Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors,”J. Clin. Invest., 113:1571-1581 (2004).
Sorensen, et al., “Glucagon Receptor Knockout Mice Display Increased Insulin Sensitivity and Impaired β-Cell Function,”Diabetes, 55:3463-3469 (2006).
Vincent, et al.,J. Cell. Biol., 107(6):65A, part 3 (1988).
Korytko Andrew Ihor
Millican, Jr. Rohn Lee
Castetter Andrea M.
Eli Lilly and Company
Goddard Laura B
Jivraj Sanjay M.
Natarajan Meera
LandOfFree
Glucagon receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Glucagon receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glucagon receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2698520